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Is there a CASTLE-AF on the hill? Additional evidence supporting atrial 
fibrillation ablation in patients with symptomatic atrial fibrillation and heart 
failure. 
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Atrial fibrillation is common in patients with heart failure and is associated with a 
worse outcome. Previous studies of rhythm control using antiarrhythmic drugs have 
not shown any prognostic benefit in atrial fibrillation. 1, 2 Even in patients with heart 
failure, the large Atrial Fibrillation Congestive heart failure trial failed to show a 
benefit of amiodarone despite a marked reduction in atrial fibrillation burden. 3 It has 
been suggested that antiarrhythmic drugs alone may not be powerful enough to 
maintain sinus rhythm, particularly in heart failure, or that the beneficial effects of 
sinus rhythm in this group are balanced by the adverse effects of antiarrhythmic 
drugs.   
 
Ablation offers a powerful treatment to restore sinus rhythm and reduce recurrent 
atrial fibrillation without requiring long-term therapy, and with synergistic effects on 
top of antiarrhythmic drugs. Early studies suggested improved exercise tolerance with 
atrial fibrillation ablation in patients with heart failure. 4 The PABA-CHF pilot trial in 
2008 compared pulmonary vein isolation to AV node ablation and biventricular 
pacing in patients with atrial fibrillation and severe heart failure. Ablation led to 
greater improvements in exercise tolerance, ejection and symptoms. 5 More recently 
the AATAC study comparing ablation with amiodarone in persistent atrial fibrillation 
confirmed these findings and also appeared to show reduced mortality in the ablation 
group. 6  
  
The recently published CATLE AF study is the largest study comparing rhythm 
control therapy by ablation to rate control therapy in patients with atrial fibrillation 
and heart failure. Over 350 patients were randomised and followed up for over 3 
years. Patients were included if they had evidence of symptomatic atrial fibrillation 
and an ejection fraction less than 35% and either an implanted defibrillator or CRT-D. 
The vast majority had either paroxysmal atrial fibrillation of persistent atrial 
fibrillation of less than one year. They also had to be intolerant of, unresponsive to, or 
unwilling to take antiarrhythmic drugs. Patients were randomized to ablation or to rate 
control therapy. 
 
The initial findings of CASTLE – AF are extremely impressive. Ablation led to an 
improvement in ejection fraction, and a transient but not sustained improvement in 6 
minute walk. More importantly ablation was associated with a significant reduction in 
mortality (13.4% compared 25%) and hospitalisation associated with heart failure, but 
had no effect on all cause hospitalization or stroke rate.  This is extremely 
encouraging and suggests a benefit of ablation in patients with atrial fibrillation and 
heart failure.  
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The use on intracardiac signals to monitor rhythm also showed the effectiveness of 
ablation to prevent recurrent atrial fibrillation. The mean atrial fibrillation burden in 
the ablation group was less than 30% with 81% having less than 5%. In contrast, 56% 
of the patients randomised to antiarrhythmic drugs were in persistent atrial fibrillation 
at the end of the trial. 
There are however a number of important caveats before rolling out ablation to all 
patients with AFib and heart failure. All the patients in the CASTLE-AF trial had 
symptomatic AFib and the majority had previously failed antiarrhythmic drug 
treatment. Over 3000 patient had to be screened to identify 363 patients to take part in 
the trial. The quality of the rate control in the pharmacological group has not been 
published and there were still active attempts to maintain sinus rhythm in this group. 
AV nodal ablation was rarely used in CASTLE-AF 7 Indeed at 5 years, 20% of the 
patients randomized to pharmacological rate control were still in sinus rhythm and 
only 56% had persistent atrial fibrillation. The mortality benefits of ablation only 
appeared relatively late on in the trial by which stage only191 of the original trial 
patients were still being followed up.  There were potentially significant differences in 
patient characteristics between the groups, with a greater incidence of diabetes and 
ischaemic cardiomyopathy. Some sub-groups also appeared to do less well with 
ablation. In particular patients with an ejection fraction of less than 25% appeared to 
have no benefit from ablation.  
Half-way up the hill. In conclusion, the CASTLE AF study further substantiates 
earlier reports that atrial fibrillation ablation is beneficial in a highly selected group of 
patients with atrial fibrillation and severe heart failure in whom antiarrhythmic drugs 
are not tolerated or ineffective. Further trials need to report before the widespread 
adoption of an ablation strategy for all patients with atrial fibrillation and heart failure.  
Data from the CABANA trial, possibly expected later this year, will provide 
information on the relative safety of ablation compared to antiarrhythmic drugs in a 
wider group of AF patients. The EAST AFNET 4 trial will provide further evidence 
of the potential prognostic benefits of early rhythm control soon after the diagnosis of 
fibrillation. Until this and other information is available, it seems worth to consider 
atrial fibrillation ablation in patients with symptomatic atrial fibrillation and severe 
heart failure on top of device therapy.  
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